Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab T-Cell Depleted Allo-SCT for Hematologic Malignancies
NCT00597714Phase 2Completed
- Start
- Feb 2008
- Primary completion
- Jul 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of alemtuzumab in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and 4 more (2 cohorts). Primary endpoint: Disease Free Survival at 2 years. Started Feb 2008; status: completed.
02
Drugs
alemtuzumab
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)leukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00597714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597714.